Cargando…
Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis
PURPOSE: Using real-world data, interstitial lung disease (ILD) prevalence before and after HER2-directed therapy was estimated. Potential ILD risk factors in patients receiving HER2-directed therapy for metastatic breast cancer (mBC) were evaluated. METHODS: Adults with HER2-directed therapy for mB...
Autores principales: | Law, Jeanna Wallenta, Campbell, Alicyn, Weller, Colin, Johanson, Colden, Broome, Ronda, Piault, Elisabeth, Izano, Monika, Schrag, Andrew, Tran, Mary, Brown, Thomas D., Kaplan, Henry G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633512/ https://www.ncbi.nlm.nih.gov/pubmed/36201127 http://dx.doi.org/10.1007/s10549-022-06738-6 |
Ejemplares similares
-
Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network
por: Law, Jeanna Wallenta, et al.
Publicado: (2022) -
The impact of functional limitations on long-term outcomes among African-American and white women with breast cancer: a cohort study
por: Izano, Monika, et al.
Publicado: (2013) -
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
por: Kaplan, Henry G., et al.
Publicado: (2022) -
Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014) -
Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
por: Colomer, R., et al.
Publicado: (2017)